Shots: Recently AstraZeneca and Amgen presented the results in late-breaking session from the COURSE trial, a proof-of-concept study evaluating tezepelumab in COPD The PoC study was carried out in people with moderately to very severe COPD with a broad range of eosinophil levels Today, at PharmaShots we have Robert Fogel from AstraZeneca, Janet Franklin from…